PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
90.50%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
74.50%
Operating income growth above 1.5x CRVO's 41.40%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
91.74%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
91.71%
EPS growth of 91.71% while CRVO is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
91.71%
Diluted EPS growth of 91.71% while CRVO is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.51%
OCF growth at 50-75% of CRVO's 79.56%. Martin Whitman would question if the firm lags in monetizing sales effectively.
55.51%
FCF growth 50-75% of CRVO's 79.56%. Martin Whitman would see if structural disadvantages exist in generating free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-103253.49%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-39279.54%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-22130.85%
Negative 3Y OCF/share CAGR while CRVO stands at 43.09%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-247692.89%
Negative 10Y net income/share CAGR while CRVO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-3218.28%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-4231.04%
Negative 3Y CAGR while CRVO is 5.49%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
4781.98%
Equity/share CAGR of 4781.98% while CRVO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
636.42%
Positive 5Y equity/share CAGR while CRVO is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
374.63%
Positive short-term equity growth while CRVO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-42.01%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-51.92%
We have a declining book value while CRVO shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-46.67%
We’re deleveraging while CRVO stands at 5.49%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-6.56%
Our R&D shrinks while CRVO invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-79.23%
We cut SG&A while CRVO invests at 158.89%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.